Age-related penetrance of hereditary atypical hemolytic uremic syndrome

Maren Sullivan1, Lisa A Rybicki, Aurelia Winter

  • 1Department of Nephrology, Section of Preventive Medicine, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany.

Annals of Human Genetics
|September 13, 2011
PubMed

Insights

Hereditary atypical hemolytic uremic syndrome (aHUS) shows reduced penetrance in relatives compared to index patients. This finding is crucial for understanding aHUS and for genetic counseling in families with these mutations.

Area of Science:

  • Genetics
  • Nephrology
  • Pediatrics

Background:

  • Hereditary atypical hemolytic uremic syndrome (aHUS) is a severe kidney disease linked to mutations in complement genes like CFH, CD46, and CFI.
  • Genetic testing of relatives is key for prevention, but clinical data for family counseling are limited.

Purpose of the Study:

  • To determine the age-adjusted penetrance of aHUS in relatives of affected individuals.
  • To provide data for improved genetic counseling regarding hereditary aHUS.

Main Methods:

  • Direct sequencing was used to screen for familial mutations in 61 relatives of 33 aHUS index patients from a German registry.
  • Demographic and clinical data were collected, and age-adjusted penetrance was calculated for CFH, CD46, and CFI mutations.

Main Results:

  • Mutations were detected in 31 of 61 relatives. Overall penetrance at age 40 was significantly lower in mutation-positive relatives (10%) compared to index patients (67%).
  • Specific penetrance reductions were observed for CFH (6% vs. 67%) and CD46 (21% vs. 70%) mutation carriers.

Conclusions:

  • Age-adjusted penetrance of hereditary aHUS is substantially lower in mutation-carrying relatives than in probands.
  • These findings are vital for understanding aHUS disease progression and for providing accurate genetic counseling to at-risk families.

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genetic Lingo01:11

Genetic Lingo

Overview
Pedigree Analysis01:35

Pedigree Analysis

Overview
Probability Laws01:49

Probability Laws

Overview
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...